This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
by Ekta Bagri
Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
by Zacks Equity Research
Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
by Sanghamitra Saha
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
by Zacks Equity Research
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Brian's Big Idea on Low Priced Stocks
by Brian Bolan
A look at low priced stocks and the Stocks Under $10 Service.
Cassava (SAVA) Up on Progress With Alzheimers Disease Study
by Zacks Equity Research
Cassava (SAVA) made positive progress with simufilam, an oral drug treatment for Alzheimer's disease dementia. The company's shares gain in the last month.
Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.
Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $36.44, moving -0.87% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $34.31, moving +0.7% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $35.92, moving -1.48% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $35.64 in the latest trading session, marking a -1.87% move from the prior day.
Cassava Sciences, Inc. (SAVA) Stock Moves -1.76%: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $43.07, moving -1.76% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $31.04, moving -1.71% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $21.72, marking a +0.14% move from the previous day.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $30.44, marking a -1.17% move from the previous day.
Cassava Sciences, Inc. (SAVA) Stock Moves -1.38%: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $26.43, marking a -1.38% move from the previous day.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $20.90, marking a -0.99% move from the previous day.
Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm
by Zacks Equity Research
Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.
Cassava Sciences, Inc. (SAVA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $38.47, moving +1.37% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $40.17 in the latest trading session, marking a -1.62% move from the prior day.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $39.08, marking a -0.13% move from the previous day.
Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $37.65, moving +0.51% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $37.31, marking a +0.54% move from the previous day.